08.06.2026
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals
Tarsus Pharmaceuticals has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, a privately held biotechnology company focused on retinal diseases that is developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease. The molecular entity is designed to reduce the accumulation of toxic dimers while preserving the normal visual cycle.